Skip to main content

Advertisement

Table 2 Disposition of patients at 12 months

From: Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Status N = 49
On treatment 37 (75.5%)
Treatment discontinued 12 (24.5%)
 Adverse events 9 (18.4%)
     Thrombocytopenia 5 (10.2%)
     Hyperbilirubinemia 2 (4.1%)
     Heart disease 1 (2.0%)
     Headache 1 (2.0%)
 No molecular response 2 (4.1%)
 Disease progression 1 (2.0%)
Median actual dose intensity, mg/day (range) 651 (198–800)